0000899243-20-006635.txt : 20200302 0000899243-20-006635.hdr.sgml : 20200302 20200302201820 ACCESSION NUMBER: 0000899243-20-006635 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200227 FILED AS OF DATE: 20200302 DATE AS OF CHANGE: 20200302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Patel Chintu CENTRAL INDEX KEY: 0001737428 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38485 FILM NUMBER: 20679480 MAIL ADDRESS: STREET 1: C/O AMNEAL PHARMACEUTICALS LLC STREET 2: 400 CROSSING BOULEVARD CITY: BRIDGEWATER STATE: CA ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001723128 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: BUSINESS PHONE: (908) 947-3120 MAIL ADDRESS: STREET 1: 400 CROSSING BOULEVARD STREET 2: 3RD FLOOR CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Atlas Holdings, Inc. DATE OF NAME CHANGE: 20171117 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-27 0 0001723128 Amneal Pharmaceuticals, Inc. AMRX 0001737428 Patel Chintu C/O AMNEAL PHARMACEUTICALS, INC. 400 CROSSING BOULEVARD, 3RD FLOOR BRIDGEWATER NJ 08807 1 1 1 0 Co-CEO and Director Performance-Based Restricted Stock Units 2020-02-27 4 A 0 1266490 0.00 A Class A Common Stock 1266490 1266490 D Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents the maximum number of shares issuable under the performance-based restricted stock units. 25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period. Exhibit 24 - Power of Attorney /s/ Meredith Cook, Attorney-in-Fact 2020-03-02 EX-24 2 attachment1.htm EX-24 DOCUMENT
                               POWER OF ATTORNEY

        Know all by these presents, that the undersigned hereby constitutes and
appoints each of (i) the General Counsel of Amneal Pharmaceuticals, Inc., a
Delaware corporation (the "Company") and who is currently Stephen Manzano, (ii)
the Company's Chief Financial Officer, who is currently Todd P. Branning, (iii)
the Company's Vice President, Transactions - Legal, who is currently Meredith
Cook, and (iv) the Company's Chief Human Resources Officer, who is currently
Nikita Shah, and their respective successors (including anyone serving in such
capacities on an interim or acting basis), signing singly, with full powers of
substitution, as the undersigned's true and lawful attorney-in-fact to:

    1.  prepare, execute in the undersigned's name and on the undersigned's
        behalf, and submit to the U.S. Securities and Exchange Commission (the
        "SEC") a Form ID, including amendments thereto, and any other documents
        necessary or appropriate to obtain codes and passwords enabling the
        undersigned to make electronic filings with the SEC of reports required
        by Section 16(a) of the Securities Exchange Act of 1934 or any rule or
        regulation of the SEC;

    2.  execute for and on behalf of the undersigned, in the undersigned's
        capacity as an officer and/or director of the Company, and/or 10% holder
        of the Company's capital stock, Forms 3, 4, and 5 and any amendments
        thereto in accordance with Section 16(a) of the Securities Exchange Act
        of 1934 and the rules thereunder;

    3.  do and perform any and all acts for and on behalf of the undersigned
        which may be necessary or desirable to complete and execute any such
        Form 3, 4, or 5, complete and execute any amendment or amendments
        thereto, and timely file such form with the SEC and any stock exchange
        or similar authority; and

    4.  take any other action of any type whatsoever in connection with the
        foregoing which, in the opinion of such attorney-in-fact, may be of
        benefit to, in the best interest of, or legally required by, the
        undersigned, it being understood that the documents executed by such
        attorney-in-fact on behalf of the undersigned pursuant to this Power of
        Attorney shall be in such form and shall contain such terms and
        conditions as such attorney-in-fact may approve in such attorney-in-
        fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to

be executed as of this 20th day of February, 2020.

                        /s/ Chintu Patel
                        -------------------------------------------------------
                        By: Chintu Patel